LifeMD Reports Third Quarter 2023 Results; Record Revenue and Adjusted EBITDA

LifeMD Reports Third Quarter 2023 Results; Record Revenue and Adjusted EBITDA

November 08, 2023 | Last Trade: US$8.26 0.10 1.23

Revenue increased 23% year-over-year to $38.6 million with both telehealth and WorkSimpli achieving record revenues.
Adjusted EPS of $0.08 per share compared with a loss of $0.03 in the year-ago period.
Consolidated adjusted EBITDA increased to $2.8 million compared with a loss of $0.8 million in the year-ago period, and a 60% improvement versus the second quarter of 2023.
Weight Management revenue more than quadrupled versus the second quarter of 2023.
Telehealth subscribers grew 22% year-over-year to a record 207,000 patients.
Conference call begins at 4:30 p.m. Eastern time today

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today reported financial results for the three and nine months ended September 30, 2023.

Management Commentary

“During the third quarter of 2023 LifeMD achieved record revenue and adjusted EBITDA, largely driven by significant patient subscriber growth. Our GLP-1 Weight Management program alone added over 8,000 net new patients, ending the quarter with over 10,000, a number that has grown to over 16,000 today. Central to this acceleration is our industry-leading telehealth technology platform, complemented by an incredible provider network spanning all 50 states,” said Justin Schreiber, Chairman and CEO of LifeMD. “Our lifestyle healthcare businesses, led by RexMD, once again posted double-digit revenue growth with robust bottom-line margins that continued to exceed 30%. We also made sizeable progress in leveraging our best-in-class platform to drive meaningful B2B partnerships, including the execution of an agreement with Ascend Therapeutics to service the women’s health market and a joint marketing and sales agreement with IQVIA leveraging LifeMD’s tremendous telehealth infrastructure with IQVIA’s comprehensive commercialization solutions. We expect to execute additional opportunities in the near future. Given our sustained record performance and LifeMD’s leadership in key telehealth markets, including weight management with GLP-1s, I believe we are extremely well positioned for continued growth next year.”

“We finished the third quarter with outstanding top- and bottom-line financial results, with revenue increasing 23% and adjusted EBITDA increasing to a record $2.8 million. For the second consecutive quarter we achieved positive cash flow from operations and exited the third quarter with our strongest balance sheet and liquidity position ever. All of these factors continue to position 2023 to be a tremendous year for LifeMD while setting the stage for what we believe will be breakout performance in 2024,” commented Marc Benathen, Chief Financial Officer of LifeMD.

Third Quarter Financial Highlights

Revenue increased 23% year-over-year to $38.6 million.
Telehealth revenue increased 14% versus the year-ago period and 9% sequentially. WorkSimpli revenue increased 42% versus the year-ago period.
Telehealth active subscribers increased 22% over the year-ago period to approximately 207,000.
Weight Management revenue more than quadrupled sequentially.
WorkSimpli active subscribers increased 14% over the year-ago period to approximately 170,000.
LifeMD branded Virtual Primary Care products and services subscribers finished the third quarter at over 26,000 with over 10,000 active patients on our GLP-1 Weight Management platform.
Gross margin expanded to a record 88%, up from 85% in the year-ago period.
GAAP net loss was $6.9 million or $0.20 per share, compared with GAAP net loss of $8.1 million or $0.26 per share in the year-ago period.
Adjusted EBITDA increased to $2.8 million compared with a loss of $0.8 million in the year-ago period (see definition below of this non-GAAP financial measure and reconciliation to GAAP).
Adjusted diluted EPS was $0.08 compared with a loss of $0.03 in the year-ago period (see definition below of this non-GAAP financial measure and reconciliation to GAAP).
Second consecutive quarter of positive cash flow from operations and exited the quarter with $15.3 million of cash.

Third Quarter Key Performance Metrics

($ in 000s)	Three Months Ended Sept 30,						Y-o-Y
Key Performance Metrics	2023			2022			% Growth
Revenue
Telehealth	$	24,343		$	21,365		14	%
WorkSimpli	$	14,271		$	10,047		42	%
Total Revenue	$	38,614		$	31,412		23	%

Subscription Revenue as % of Total		96	%		95	%	1	%

Active Subscribers
Telehealth Active Subscribers		206,536			169,916		22	%
WorkSimpli Active Subscribers		170,388			149,095		14	%
Total Active Subscribers		376,924			319,011		18	%

Financial Guidance

For the fourth quarter of 2023, the Company expects:

Revenue to be between $40 million and $41 million.
Adjusted EBITDA to be between $3 million and $4 million.

For the full year 2023, the Company expects:

Revenue to be between $148 million and $149 million.
Adjusted EBITDA to be between $10 and $11 million.

Guidance for 2023 includes a $4.0 million impact of deferred revenue related to GAAP accounting rules for the Weight Management business. Net of this impact, both revenue and adjusted EBITDA would be higher by $4.0 million.

Conference Call

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

Toll-free dial-in number:		877-704-4453
International dial-in number:		201-389-0920
Conference ID:		13741419

A replay of the webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About LifeMD

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact
LifeMD, Inc.
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Tables to Follow


LIFEMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2023			December 31, 2022
	(Unaudited)
ASSETS

Current Assets
Cash	$	15,288,330		$	3,958,957
Accounts receivable, net		4,418,582			2,834,750
Product deposit		84,768			127,265
Inventory, net		3,790,646			3,703,363
Other current assets		1,303,960			687,022
Total Current Assets		24,886,286			11,311,357

Non-current Assets
Equipment, net		424,637			476,441
Right of use asset		799,104			1,206,009
Capitalized software, net		11,325,766			8,840,187
Intangible assets, net		3,255,231			3,831,859
Total Non-current Assets		15,804,738			14,354,496

Total Assets	$	40,691,024		$	25,665,853

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts payable	$	9,637,390		$	10,106,793
Accrued expenses		15,493,128			12,166,509
Notes payable, net		426,223			2,797,250
Current operating lease liabilities		725,832			756,093
Deferred revenue		6,239,354			5,547,506
Total Current Liabilities		32,521,927			31,374,151

Long-term Liabilities
Long-term debt, net		18,827,283			-
Noncurrent operating lease liabilities		169,821			574,136
Contingent consideration		256,250			443,750
Purchase price payable		-			579,319
Total Liabilities		51,775,281			32,971,356

Commitments and Contingencies
Mezzanine Equity
Preferred Stock, $0.0001 par value; 5,000,000 shares authorized
Series B Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero and 3,500 shares issued and outstanding, as of September 30, 2023 and December 31, 2022, respectively. Liquidation value approximately $0 and $1,305 per share as of September 30, 2023 and December 31, 2022, respectively		-			4,565,822

Stockholders’ Deficit
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately $29.44 and $27.84 per share as of September 30, 2023 and December 31, 2022, respectively		140			140
Common Stock, $0.01 par value; 100,000,000 shares authorized, 34,759,250 and 31,552,775 shares issued, 34,656,210 and 31,449,735 outstanding as of September 30, 2023 and December 31, 2022, respectively		347,593			315,528
Additional paid-in capital		196,901,377			179,015,250
Accumulated deficit		(209,756,573	)		(190,562,994	)
Treasury stock, 103,040 and 103,040 shares, at cost, as of September 30, 2023 and December 31, 2022, respectively		(163,701	)		(163,701	)
Total LifeMD, Inc. Stockholders’ Deficit		(12,671,164	)		(11,395,777	)
Non-controlling interest		1,586,907			(475,548	)
Total Stockholders’ Deficit		(11,084,257	)		(11,871,325	)
Total Liabilities, Mezzanine Equity and Stockholders’ Deficit	$	40,691,024		$	25,665,853

LIFEMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenues
Telehealth revenue, net	$	24,342,789		$	21,365,178		$	66,896,719		$	66,231,202
WorkSimpli revenue, net		14,271,122			10,047,291			40,790,439			24,682,602
Total revenues, net		38,613,911			31,412,469			107,687,158			90,913,804
Cost of revenues
Cost of telehealth revenue		4,479,760			4,502,919			12,525,887			14,042,112
Cost of WorkSimpli revenue		301,746			213,923			1,019,018			558,216
Total cost of revenues		4,781,506			4,716,842			13,544,905			14,600,328

Gross profit		33,832,405			26,695,627			94,142,253			76,313,476

Expenses
Selling and marketing expenses		19,776,797			17,200,859			56,062,345			60,928,649
General and administrative expenses		13,398,387			12,385,030			36,120,723			37,757,710
Other operating expenses		1,622,137			1,617,375			4,640,690			5,076,820
Customer service expenses		2,106,252			1,488,428			5,573,734			3,428,098
Development costs		1,498,213			821,636			4,062,498			1,951,039
Goodwill impairment charge		-			-			-			2,735,000
Change in fair value of contingent consideration		-			248,000			-			(2,487,000	)
Total expenses		38,401,786			33,761,328			106,459,990			109,390,316

Operating loss		(4,569,381	)		(7,065,701	)		(12,317,737	)		(33,076,840	)

Other expenses
Interest expense, net		(713,766	)		(132,235	)		(1,973,901	)		(432,405	)
(Loss) gain on debt extinguishment		-			-			(325,198	)		63,400

Net loss		(5,283,147	)		(7,197,936	)		(14,616,836	)		(33,445,845	)

Net income attributable to noncontrolling interests		839,288			83,737			2,247,055			154,464

Net loss attributable to LifeMD, Inc.		(6,122,435	)		(7,281,673	)		(16,863,891	)		(33,600,309	)

Preferred stock dividends		(776,563	)		(776,563	)		(2,329,688	)		(2,329,688	)

Net loss attributable to LifeMD, Inc. common stockholders	$	(6,898,998	)	$	(8,058,236	)	$	(19,193,579	)	$	(35,929,997	)

Basic loss per share attributable to LifeMD, Inc. common stockholders	$	(0.20	)	$	(0.26	)	$	(0.58	)	$	(1.17	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders	$	(0.20	)	$	(0.26	)	$	(0.58	)	$	(1.17	)

Weighted average number of common shares outstanding:
Basic		34,472,904			30,935,643			32,959,665			30,830,533
Diluted		34,472,904			30,935,643			32,959,665			30,830,533

LIFEMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(5,283,147	)	$	(7,197,936	)	$	(14,616,836	)	$	(33,445,845	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount		79,653			-			233,495			-
Amortization of capitalized software		1,439,049			770,873			3,787,716			1,746,899
Amortization of intangibles		245,968			325,495			725,496			666,782
Accretion of consideration payable		34,265			37,373			148,481			172,741
Depreciation of fixed assets		49,852			43,761			146,286			117,008
Loss (gain) on debt extinguishment		-			-			325,198			(63,400	)
Change in fair value of contingent consideration		-			248,000			-			(2,487,000	)
Goodwill impairment charge		-			-			-			2,735,000
Operating lease payments		191,645			172,836			562,073			463,198
Stock issued for legal settlement		532,000			816,000			532,000			816,000
Stock compensation expense		3,318,253			3,336,213			8,843,736			11,850,000

Changes in Assets and Liabilities
Accounts receivable		(750,039	)		(24,491	)		(1,583,832	)		(1,558,063	)
Product deposit		150,347			332,790			42,497			95,505
Inventory		(92,344	)		(710,889	)		(87,283	)		(2,052,363	)
Other current assets		(631,765	)		58,629			(616,938	)		(21,386	)
Change in operating lease liability		(201,667	)		(167,644	)		(589,744	)		(378,095	)
Deferred revenue		571,144			360,650			691,848			853,272
Accounts payable		44,011			(1,026,708	)		(469,403	)		1,827,103
Accrued expenses		1,378,992			(150,954	)		5,611,131			(2,303,466	)
Other operating activity		-			-			(579,319	)		-
Net cash provided by (used in) operating activities		1,076,217			(2,776,002	)		3,106,602			(20,966,110	)

CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for capitalized software costs		(2,373,443	)		(2,220,018	)		(6,273,295	)		(6,742,946	)
Purchase of equipment		(30,263	)		(21,546	)		(94,482	)		(378,877	)
Purchase of intangible assets		-			-			(148,868	)		(4,000,500	)
Acquisition of business, net of cash acquired		-			-			-			(1,012,395	)
Net cash used in investing activities		(2,403,706	)		(2,241,564	)		(6,516,645	)		(12,134,718	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from long-term debt, net		4,993,885			-			19,466,887			-
Proceeds from notes payable		347,691			-			2,347,691			-
Sale of common stock under ATM, net		899,567			-			899,567			-
Repayment of notes payable, net of prepayment penalty		(657,002	)		-			(5,043,916	)		-
Cash proceeds from exercise of options		-			-			-			90,400
Cash proceeds from exercise of warrants		-			-			-			38,500
Preferred stock dividends		(776,563	)		(776,563	)		(2,329,688	)		(2,329,688	)
Contingent consideration payment for ResumeBuild		(62,500	)		(62,500	)		(187,500	)		(93,750	)
Net payments for membership interest of WorkSimpli		-			12,150			(305,625	)		12,150
Distributions to non-controlling interest		(36,000	)		(36,000	)		(108,000	)		(108,000	)
Net cash provided by (used in) financing activities		4,709,078			(862,913	)		14,739,416			(2,390,388	)

Net increase (decrease) in cash		3,381,589			(5,880,479	)		11,329,373			(35,491,216	)

Cash at beginning of period		11,906,741			11,717,302			3,958,957			41,328,039

Cash at end of period	$	15,288,330		$	5,836,823		$	15,288,330		$	5,836,823

Cash paid for interest
Cash paid during the period for interest	$	717,054		$	-		$	1,485,242		$	-

Non-cash investing and financing activities:
Warrants issued for debt instruments	$	(215,243	)	$	-		$	873,100		$	-
Cashless exercise of options	$	579		$	42		$	744		$	297
Consideration payable for Cleared acquisition	$	-		$	-		$	-		$	8,079,367
Consideration payable for ResumeBuild acquisition	$	-		$	-		$	-		$	500,000
Stock issued for noncontingent consideration payment	$	642,000		$	-		$	1,926,000		$	-
Series B Preferred Stock conversion	$	5,072,814		$	-		$	5,072,814		$	-
Principal of Paycheck Protection Program loans forgiven	$	-		$	-		$	-		$	63,400
Right of use asset	$	62,053		$	-		$	155,168		$	-
Right of use lease liability	$	62,053		$	-		$	155,168		$	-

About the Use of Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA and adjusted EPS as non-GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

Adjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, inventory valuation, sales return reserves, litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its most directly comparable GAAP financial measure.

Adjusted EPS is defined as the diluted net loss attributable to LifeMD, Inc common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, inventory valuation, sales return reserves, litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EPS to Diluted loss per share attributable to LifeMD, Inc common shareholders, its most directly comparable GAAP financial measure.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA and adjusted EPS may vary from that of others in our industry. Adjusted EBITDA and adjusted EPS should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.


Reconciliation of GAAP Net Loss to Adjusted EBITDA
(in whole numbers, unaudited)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Net loss attributable to common shareholders	$	(6,898,998	)	$	(8,058,236	)	$	(19,193,579	)	$	(35,929,997	)

Interest expense (excluding amortization of debt discount)		594,229			17,550			1,233,415			92,090
Depreciation, amortization and accretion expense		1,769,134			1,177,502			4,807,979			2,703,430
Amortization of debt discount		79,653			-			233,495			-
(Gain) loss on debt extinguishment		-			-			325,198			(63,400	)
Financing transactions expense		305,424			-			735,501			152,015
Litigation costs		420,404			813,000			1,426,330			1,517,359
Inventory and reserve adjustment		-			-			232,630			230,661
Severance costs		7,692			-			7,692			179,090
Acquisitions expenses		86,942			-			127,138			265,153
Change in fair value of contingent consideration		-			248,000			-			(2,487,000	)
Goodwill impairment charge		-			-			-			2,735,000
Insurance acceptance readiness		8,094			-			66,634			-
Sarbanes Oxley readiness		48,576			-			48,576			-
Accrued interest on Series B Convertible Preferred Stock		39,884			114,685			506,991			340,315
Foreign exchange (gain) loss		272,899			685,242			796,619			685,242
Taxes		70,378			-			70,378			-
Dividends		1,813,130			776,563			3,971,890			2,329,688
Stock-based compensation expense		3,318,253			3,336,213			8,843,736			11,850,000
Net income attributable to noncontrolling interests		839,288			83,737			2,247,055			154,464

Adjusted EBITDA	$	2,774,982		$	(805,744	)	$	6,487,678		$	(15,245,890	)


Reconciliation of GAAP Diluted Loss per Share Attributable to Common Shareholders to Adjusted EPS
(unaudited)	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Diluted loss per share attributable to LifeMD, Inc. common shareholders	$	(0.20	)	$	(0.26	)	$	(0.58	)	$	(1.17	)

Adjustments to Reconcile GAAP Diluted Loss Per Share to Adjusted EPS
Interest expense (excluding amortization of debt discount)		0.02			-			0.04			-
Depreciation, amortization and accretion expense		0.05			0.04			0.15			0.09
Amortization of debt discount		-			-			0.01			-
Loss on debt extinguishment		-			-			0.01			-
Financing transactions expense		0.01			-			0.02			-
Litigation costs		0.01			0.03			0.04			0.05
Inventory and reserve adjustment		-			-			0.01			0.01
Severance costs		-			-			-			0.01
Acquisitions expenses		-			-			-			0.01
Change in fair value of contingent consideration		-			0.01			-			(0.08	)
Goodwill impairment charge		-			-			-			0.09
Insurance acceptance readiness		-			-			-			-
Sarbanes Oxley readiness		-			-			-			-
Accrued interest on Series B Convertible Preferred Stock		-			-			0.02			0.01
Foreign exchange (gain) loss		0.01			0.02			0.02			0.02
Taxes		-			-			-			-
Dividends		0.05			0.02			0.12			0.08
Stock-based compensation expense		0.10			0.11			0.27			0.38
Net income attributable to noncontrolling interests		0.03			-			0.07			0.01

Adjusted EPS	$	0.08		$	(0.03	)	$	0.20		$	(0.49	)

Stock Quote

Last Trade:	US$8.26
Daily Change:	0.10 1.23
Daily Volume:	1,340,365
Market Cap:	US$348.490M

May 06, 2025 LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance April 28, 2025 LifeMD Acquires Women’s Health Provider Optimal Human Health MD to Accelerate Entry into the Women’s Health Market March 10, 2025 LifeMD Reports Fourth Quarter 2024 Results March 06, 2025 LifeMD Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound November 07, 2024 LifeMD Reports Third Quarter 2024 Results LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE